Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Tempus AI, Inc. Class A Common Stock (TEM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: TEM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -54.56% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 9.00B USD | Price to earnings Ratio - | 1Y Target Price 56.89 |
Price to earnings Ratio - | 1Y Target Price 56.89 | ||
Volume (30-day avg) 12658176 | Beta - | 52 Weeks Range 22.89 - 91.45 | Updated Date 03/8/2025 |
52 Weeks Range 22.89 - 91.45 | Updated Date 03/8/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.16 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -116.06% | Operating Margin (TTM) -29.63% |
Management Effectiveness
Return on Assets (TTM) -58.65% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 9009540609 | Price to Sales(TTM) 14.06 |
Enterprise Value 9009540609 | Price to Sales(TTM) 14.06 | ||
Enterprise Value to Revenue 14.07 | Enterprise Value to EBITDA - | Shares Outstanding 152402000 | Shares Floating 71623616 |
Shares Outstanding 152402000 | Shares Floating 71623616 | ||
Percent Insiders 56.75 | Percent Institutions 32.35 |
Analyst Ratings
Rating 4.1 | Target Price 45.86 | Buy 3 | Strong Buy 4 |
Buy 3 | Strong Buy 4 | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Tempus AI, Inc. Class A Common Stock
Company Overview
History and Background
Tempus AI, Inc. is a technology company focused on precision medicine through data and artificial intelligence. Founded in 2015, Tempus aims to revolutionize healthcare by creating a vast library of molecular and clinical data and building analytical tools to deliver personalized treatments.
Core Business Areas
- Genomic Sequencing: Tempus offers genomic sequencing services to healthcare providers, enabling the identification of genetic markers relevant to disease diagnosis and treatment. Key to providing personalized medical treatment.
- Clinical Data Aggregation: Tempus aggregates clinical data from various sources, including electronic health records and imaging data, to create a comprehensive view of patient health. Making it available for providers to make precise diagnoses.
- AI-Driven Analysis: Tempus utilizes artificial intelligence and machine learning to analyze genomic and clinical data, identifying patterns and insights that can inform treatment decisions.
- Therapeutic Development: Tempus has partnerships with pharmaceutical companies in the use of their tools to inform the correct therapies.
Leadership and Structure
Eric Lefkofsky is the founder and CEO. The company operates with a structure that emphasizes data science, clinical expertise, and technology development.
Top Products and Market Share
Key Offerings
- Tempus|xT: A comprehensive genomic sequencing test for cancer patients. This helps oncologists identify actionable mutations and treatment options. Market share estimates are difficult to ascertain due to the fragmented nature of the precision medicine market, but xT is considered a leading product. Competitors include Foundation Medicine (FMI), Guardant Health (GH).
- Tempus|One: A clinical data platform that aggregates and analyzes patient information from various sources. This provides clinicians with a holistic view of patient health and facilitates personalized treatment decisions. Competitors include Flatiron Health (acquired by Roche), and various EHR vendors building analytical capabilities.
Market Dynamics
Industry Overview
The precision medicine industry is rapidly growing, driven by advances in genomics, data analytics, and artificial intelligence. The industry is characterized by intense competition and evolving regulatory landscape.
Positioning
Tempus is positioned as a leader in precision medicine, offering a comprehensive platform that integrates genomic sequencing, clinical data, and AI-driven analysis. Its competitive advantages include its vast data library and its ability to generate actionable insights.
Total Addressable Market (TAM)
The global precision medicine market is projected to reach hundreds of billions USD. Tempus AI, Inc. is positioned to capture a significant portion of this market due to its broad service offering.
Upturn SWOT Analysis
Strengths
- Comprehensive data platform
- AI-driven analysis capabilities
- Strong partnerships with healthcare providers and pharmaceutical companies
- Experienced leadership team
Weaknesses
- High operating expenses
- Limited profitability
- Dependence on key partnerships
- Regulatory uncertainty
Opportunities
- Expansion into new therapeutic areas
- Development of new AI-driven diagnostic and treatment tools
- Increased adoption of precision medicine by healthcare providers
- Partnerships with additional pharmaceutical companies
Threats
- Competition from established players in the genomics and data analytics industries
- Rapid technological advancements
- Changes in healthcare regulations
- Economic downturn
Competitors and Market Share
Key Competitors
- FMI
- GH
- RO.SW
Competitive Landscape
Tempus competes with larger, established players and smaller, niche providers. Its strength lies in its integrated platform and AI capabilities, while its weaknesses include its high operating expenses and limited profitability.
Major Acquisitions
acquired company is unnamed
- Year: 2020
- Acquisition Price (USD millions): 0
- Strategic Rationale: Tempus has publicly stated it has acquired several companies over the years, but has not released the name and value for these acquisitions.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data unavailable as the company is recently public.
Future Projections: Future projections are not yet widely available from analyst estimates.
Recent Initiatives: Recent initiatives include expanding partnerships with pharmaceutical companies and launching new AI-driven diagnostic tools.
Summary
Tempus AI, Inc. is a key player in the fast-growing precision medicine industry. The companyu2019s integrated platform that combines genomics, data analytics and AI-driven solutions is highly valued by healthcare providers and pharmaceutical companies. While Tempus shows strong market potential, profitability remains a key challenge. Economic downturns and new players entering the industry could affect future growth.
Similar Companies
GH
Guardant Health Inc
GH
Guardant Health Inc
ILMN
Illumina Inc
ILMN
Illumina Inc
PACB
Pacific Biosciences of California
PACB
Pacific Biosciences of California
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Market research reports
- Analyst estimates
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market share data is based on estimates and may not be precise. Financial performance and growth projections are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tempus AI, Inc. Class A Common Stock
Exchange NASDAQ | Headquaters Chicago, IL, United States | ||
IPO Launch date 2024-06-14 | Co-Founder, CEO, President & Chairman Mr. Eric P. Lefkofsky | ||
Sector Healthcare | Industry Health Information Services | Full time employees 2400 | Website https://www.tempus.com |
Full time employees 2400 | Website https://www.tempus.com | ||
Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.